“LAG525”的意思、由来-开放百科全书

词条

LAG525

释义

References

{{Orphan|date=July 2015}}LAG525 is a monoclonal antibody being developed by Novartis for the treatment of cancer. The antibody targets the immune checkpoint LAG-3, which is expressed on T cells and tends to down-regulate an immune response. In a June 2015 presentation Novartis management indicated that 'dosing is imminent' for the first clinical trials of LAG525.^[1]

LAG525's first clinical trial is a Phase I in expected to be in patients with various solid tumors, in combination with PDR001, an anti-PD-1 monoclonal antibody. (ClinicalTrials.gov identifier NCT02460224).

References

1. ^{{cite web|title=Meet Novartis Management presentation, 17/18 June 2015|url=https://www.novartis.com/sites/www.novartis.com/files/2015-06-meet-the-management-2-pharma.pdf|publisher=Novartis|accessdate=9 July 2015}}

2 : Cancer treatments|Monoclonal antibodies

随便看

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。